( period. The medications evaluatedinclu...)New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate,Health

A review of this data found that OROS(R) methylphenidate had a lower frequency of emergency department reports of abuse compared to other methylphenidate formulations. Furthermore, DAWN found that of all ADHD treatments, non-methylphenidate stimulants (e.g., amphetamines, mixed amphetamine salts) had the most emergency department reports of abuse.

The DAWN data highlights the "abuse-to-prescribed-use" ratio of ADHD drugs, in which OROS(R) methylphenidate was lower than that of other methylphenidate formulations, and similar to that of atomoxetine. The study found the highest abuse-to-prescribed-use ratio among non-methylphenidate stimulant formulations(1). (The abuse-to-prescribe-ratio was determined by dividing reported emergency department visits for abuse by the number of prescriptions dispensed for each type of ADHD drug during the three-year period.)

Overall findings showed that of the 1,102 reports of abuse gathered, long-acting OROS(R) methylphenidate had the least number of reports (89), compared with other long- and short-acting methylphenidate formulations (301), and non-methylphenidate stimulants (651). Only the non-stimulant drug, atomoxetine, had a lower number of overall reports at 61.

Pharmacokinetics and Pharmacodynamics of Abuse Potential (APA Poster Board NR525)

The other data presented Tuesday found that long-acting OROS(R) methylphenidate produced lower abuse-related subjective effects compared to immediate-release methylphenidate at comparable total doses. In this double-blind, placebo-controlled, randomized, crossover study, 49 occasional stimulant-abusing adults were given 50 mg and 90 mg doses of immediate-release methylphenidate and 54 mg and 108 mg doses of OROS(R) methylphenidate. The long-acting OROS(R) methylphenidate formulation releases
'"/>